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Circulating tumor cells (CTCs) are prognostic markers in a variety of solid tumor malig-
nancies. The potential of CTCs to be used as a “liquid biopsy” to monitor a patient’s
condition and predict drug response and resistance is currently under investigation. Using
a negative depletion, enrichment methodology, CTCs isolated from the peripheral blood
of breast cancer patients with stage IV breast cancer undergoing DNA damaging therapy
with platinum-based therapy were enriched. The enriched cell suspensions were stained
with an optimized labeling protocol targeting: nuclei, cytokeratins 8, 18, and 19, the sur-
face marker CD45, and the presence of the protein γ-H2AX. As a direct or indirect result
of platinum therapy, double-strand break of DNA initiates phosphorylation of the histone
H2AX, at serine 139; this phosphorylated form is referred to as γ-H2AX. In addition to γ-
H2AX staining in speciﬁc locationswith the cell nuclei, consistent with previous reports and
referred to as foci, more general staining in the cell cytoplasm was also observed in some
cells suggesting the potential of cell apoptosis. Our study underscores the utility and the
complexity of investigating CTCs as predictive markers of response to various therapies.
Additional studies are ongoing to evaluate the diverse γ-H2AX staining patterns we report
here which needs to be further correlated with patient outcomes.
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INTRODUCTION
Circulating tumor cells (CTCs) have been isolated in the periph-
eral blood samples of patients with various kinds of solid tumor
malignancies, and elevated CTC numbers correlate with adverse
clinical outcomes (Pantel and Alix-Panabieres, 2007). While there
is an accumulating body of evidence supporting CTCs as prog-
nostic biomarkers, their role as predictive markers of response to
various chemotherapeutic agents is currently under investigation.
One such area iswhethermeasuring changes in speciﬁcmarkers on
CTCs during chemotherapy can select the patients who are most
likely to derive beneﬁt from a speciﬁc chemotherapy regimen. One
such marker of interest is γ-H2AX.
In higher eukaryotic cells, double-strand breaks (DSBs) in
DNA within chromatin quickly (within minutes) initiate the
phosphorylation of the histone H2AX, at serine 139 at its C-
terminus, to generate γ-H2AX. It is further noted that a single
strand break of DNA can elicit a cellular mechanism that will
cut the other DNA strand resulting in, effectively, a DSB. The
phosphorylated form of H2AX forms foci. All cells in the body
contain background foci as a result of the presence of reactive
oxygen species, collapsed replication forks, eroded telomeres and
depending on cell type, and growth conditions. The foci can
be visualized with antibodies to γ-H2AX with each DSB yield-
ing one focus (Nakamura et al., 2006). H2AX phosphorylation
and γ-H2AX foci formation are now generally accepted as con-
sistent and quantitative markers of DSBs, applicable even under
conditions where only a few DSBs are present (Rothkamm and
Lobrich, 2003).
γ-H2AX focal growth was ﬁrst studied in Muntiacus muntjak
cells. Small foci appeared 3 min after exposure to ionizing radia-
tion (IR). The foci became brighter and larger at 9 min after IR,
and reached maximal brightness and size 30 min after IR. These
ﬁndings suggest that H2AX molecules in a small region near the
DSB site are phosphorylated ﬁrst, and are followed by molecules
at increasing distances from the break site. Thus, foci are sites
of accumulation for many factors involved in DNA repair and
chromatin remodeling (Nakamura et al., 2006; Bonner et al., 2008;
Kinner et al., 2008). There is a close correlation between γ-H2AX
foci and DNA DSB numbers and between the rate of foci loss and
DSB repair, providing a potentially sensitive assay tomonitorDNA
damage.
It is this association between γ-H2AX foci andDNADSB num-
bers that has lead researchers to suggest that the detection of
γ-H2AX foci in CTCs as a rapid method to assess the effectiveness
of chemotherapeutic agents that induce DSB (Wang et al., 2010).
Such a use of CTCs is consistent with a general term being used to
describe the collection of CTCs as a “liquid biopsies”; potentially
allowing near real time analysis of the action of chemotherapy
agents on the patient cancer cells.
The initial study of γ-H2AX expression in CTC by Wang
et al. (2010), and further studies by Kummar et al. (2011, 2012)
used the FDA approved, positive selection technology for CTCs,
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FIGURE 1 | Flow chart of the CTC enrichment methodology.
CellSearchTM, for initial isolation of CTC prior to staining for
γ-H2AX. While demonstrated to be effective in isolation of CTCs
expressing the epithelial cells surface marker, EpCAM, signiﬁcant
experimental evidence is developing which suggests that poten-
tial CTCs are present in blood of cancer patients that do not
express EpCAM (Sieuwerts et al., 2009; Konigsberg et al., 2011;
Balasubramanian et al., 2012).
To address this bias in only selecting EpCAM positive cells, a
purely negative depletion, enrichment approach was developed in
which red blood cells are removed, and high expressing CD45 cells
are removed in a ﬂow through, high ﬁeld magnetic quadrupole
ﬁeld (Lara et al., 2004; Yang et al., 2009). With this system, Jatana
et al. (2010) presented results suggesting the prognostic signiﬁ-
cance of CTCs in squamous cell carcinoma of the head and neck
(SCCHN) patients.
Given the initial success of this negative enrichment approach,
we developed and optimized the staining protocol for evaluating
γ-H2AX expression on CTCs stained using non-EpCAM positive
selection which has not been previously described.
MATERIALS AND METHODS
CELL LINES
Two breast cancer cell lines, MCF-7 and MDA-MB-231, were pro-
cured from ATCC (Manassas, VA, USA) and grown to mid-log
phase in Dulbecco’s Modiﬁed Eagle Medium (DMEM; Cat#10-
013,Mediatech,Manassas,VA,USA), supplementedwith 10% fetal
bovine serum (FBS; Cat#30-2020, ATCC,Manassas,VA,USA) and
MEM nonessential amino acids (Cat#25-025, Mediatech, Manas-
sas, VA, USA) at 37◦C in a humidiﬁed atmosphere containing 5%
CO2. Cells were harvested by washing the adherent cells with PBS
and subsequently incubating with AccutaseTM (Cat#AT104, Inno-
vative Cell Technologies, Inc.) for 5 min at 37◦C to remove the
attached cells from the T-ﬂask. The Accutase was then neutralized
with the culture media before pelleting the cells at 350 × g for
5 min.
PATIENT SAMPLES
Representative samples of CTCs from the peripheral blood of
breast cancer patients with stage IV breast cancer undergoingDNA
damaging therapy with platinum-based therapy were selected
(OSU IRB protocol 2008C0129).
REAGENTS USED FOR CELL SEPARATION
The blood cell suspension, after RBC lysis was labeled with
tetrameric antibody complexes (TACs) from Stem Cell technolo-
gies (Cat.# 18259, Vancouver, BC, Canada). The speciﬁc TACs
used in this study were a pan-leukocyte marker that targets differ-
ent isoforms of the CD45 cell surface antigen and dextran coated
magnetic nanoparticles.
SEPARATION/ENRICHMENT METHODOLOGY
The immunomagnetic separation was carried out as described in
Yang et al. (2009) and will only be brieﬂy summarized here. An
overall view of the separation process is shown in Figure 1. Red
blood cells in the samples were lysed by mixing the sample with
Table 1 | Antibodies and fluoroprobes used in this study.
Target Antibody clone Manufacturer/Cat# Fluoroprobe Secondary antibody Manufacturer/Cat# Fluoroprobe





AF488 – – –
CD45 Rabbit, polyclonal Abcam (ab10558) – Donkey anti-rabbit Invitrogen (A-31573) AF647
Phospho-histone
H2A.X (Ser139)
Clone JBW301 Millipore (05-636) – Goat anti-mouse IgG
(H + L)
Invitrogen (A-11005) Alexa Fluor 594
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Table 2 | Optimized labeling protocol.
1. Prepare cytospin slide of enriched cell sample
2.Wash 1 × 5 min in PBST (PBS + 0.05%Tween 20)
3. Add permeabilization/blocking solution (PBS + 2% normal goat serum + 2% normal donkey serum + 1% BSA + 0.1% gelatin + 0.1%Triton
X-100 + 0.05%Tween 20) for 30 min at room temperature
4. Add primary anti-CD45 (rabbit, polyclonal, 1:100) and primary anti-phospho-histone-H2A.X (Ser139; mouse, clone JBW301, 1:100) in antibody diluent,
background reducing (Dako, Carpinteria, CA, USA) for 1 h at RT
5.Wash 3 × 5 min in PBST
6. Add secondary Alexa Fluor 647 donkey anti-rabbit IgG (H + L) and secondary Alexa Fluor 594 goat anti-mouse IgG (H + L) in PBST for 1 h at RT
7. Wash 2 × 5 min in PBST
8. Add custom-conjugated cytokeratin 8, 18, 19-Alexa Fluor 488 (clone CK3-6H5, 1:100) in 1% BSA/PBS for 1 h at RT
9.Wash 2 × 5 min in PBST
10. Mount with ProLong Gold antifade reagent with DAPI (Life Technologies, Grand Island, NY, USA)
FIGURE 2 | Sets of epifluorescent images (A–F) for MCF-7 and (G–L) for MDA-MB-231. For (A–F) and (G–K), images are the same location, different ﬁlter
settings corresponding to the stained marker/structure targeted and listed above the image. Figures (F) and (L) are the enlargements highlighted (E) and (K),
respectively.
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lysis buffer (154 mMNH4Cl, 10 mMNaHCO3, 0.1 mM EDTA) at
a ratio of 1:20, incubating it for 5 min at room temperature, and
then pelleting the remaining blood cells at 350 × g for 5 min.
This cell pellet, consisting mostly of nucleated cells, was then
labeled with 0.5 μl of anti-CD45 TAC per one million cells for
30 min at room temperature on a shaker. Without washing the
cells, 1 μl per one million cells of the magnetic nanoparticles were
added to the cell suspension and incubated for 15 min at room
temperature on a shaker. The immunomagnetically labeled cell
suspension was subsequently diluted with 10 ml of buffer and run
through the our previously developed, and reported, magnetic
deposition system (Lara et al., 2004; Yang et al., 2009; Balasubra-
manian et al., 2012).
The ﬁnal cell suspension, which had passed through the mag-
netic sorter, was thenmeasured for volume and the cell suspension
was split into two aliquots; one of which was subsequently sub-
jected to cell lysis and RNA preservation procedures and the other
either directly cytospun for analysis or preserved with 10% neu-
tral buffered formalin for later concentration and ICC analysis.
Final cell numbers were obtained by diluting 10 μl of the enriched
cell suspension in 3% acetic acid (1:10 dilution) and counting the
number of total cells present using a hemocytometer.
REAGENTS, LABELING PROTOCOL, AND MICROSCOPIC IMAGING
Table 1 lists the antibodies used for immunocytochemistry in this
study and Table 2 lists the optimized labeling protocol. An epi-
ﬂuorescent microscope (Nikon Eclipse 80i; Melville, NY, USA)
was used for image analysis using the manufacturer supplied
NIS-Elements software.
RESULTS
POSITIVE CONTROLS: MCF-7 AND MDA-MB-213 CELLS EXPRESSING
γ-H2AX FOCI
Figure 2 presents individual images, using appropriate excitation
and emission, for each ﬂuoroprobe as well as an electronically
combined, and ﬁnally an electronically enlarged image of MCF-7
cells stained with the optimized labeling protocol (Figures 2A–F,
respectively). Figures 2G–LpresentedDAPI stained and combined
staining of MDA-MB-231 cell line.
NEGATIVE CONTROLS
For a negative control, images of buffy coat and fresh, normal,
human blood is presented in Figure 3. Note the images presented
are not truly a representative image; the vast majority of cells
(greater than 1 in 1000) donot stain for peripheral or foci γ-H2AX.
FIGURE 3 | Sets of epifluorescent images (A–F) for buffy coat and (G–L) for fresh, normal blood. For (A–F) and (G–K), images are the same location,
different ﬁlter settings corresponding to the stained marker/structure targeted and listed above the image. Figures (F) and (L) are the enlargements highlighted
(E) and (K), respectively.
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The speciﬁc imageswere chosen to demonstrate that normal blood
cells can have γ-H2AX staining; however, none of these γ-H2AX
stained cells also co-stained for cytokeratins.
PATIENT SAMPLES
Figure 4 are representative images of the different types of cell
staining observed, including: (1) a traditional CTC with γ-H2AX,
nuclear, foci staining, (2) a traditional CTC with only peripheral
γ-H2AX staining, (3) a CTC with γ-H2AX, nuclear, foci and
peripheral staining, and (4) a cohesive cluster of cells suggestive of
tumor embolus that exhibits traditional CTC characteristics and
γ-H2AX, nuclear, foci staining. In addition, there exists in many
patient samples cells which exhibit staining for all the markers,
including CD45.
FIGURE 4 | Representative images of the different types of staining
patterns observed in peripheral blood samples taken from metastatic
breast cancer patients undergoing a phase I, two drug trail. Each
sample was from a different patient; yet these images represent
the range of types of cells seen in a majority of patients and time
points.
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DISCUSSION
Using our optimized staining protocol, on samples obtained
using an enrichment methodology which depleted normal (RBCs
and CD45 expressing) cells, we successfully illustrated the pres-
ence of γ-H2AX expression on CTCs in patients with metastatic
breast cancer undergoing DNA damaging chemotherapy with
platinums. Our multiparameter ICC staining targeted (a) the
cell nuclei, (b) cytokeratins 8, 18, and 19, (c) γ-H2AX foci,
and (d) CD45. Unlike many other ICC studies of CTCs, we
only used speciﬁc Alexa Fluor dyes, which have a very low
rate of photo bleaching and with very low crosstalk between
channels. Using this protocol, we observed various staining pat-
terns, represented by the six different sets of images presented in
Figure 4.
Further, the distinction between peripheral versus nuclear foci,
γ-H2AX staining of cells, as well as the presence of weak CD45
staining on some of the cells, demonstrate the complexity of this
type of analysis. While it has been previously reported in the liter-
ature that the occurrence of γ-H2AX staining in cells from healthy
patients can occur, and as we report in Figure 3, we did not see in
normal cells positive staining for all four markers including cytok-
eratin staining. In addition, in these cells from healthy patients, we
did not see γ-H2AX foci staining in the nuclei. However, Figure 4
does indicate that in addition to seeing traditionalCTC(i.e., nuclei,
cytokeratin positive, and CD45 negative) with γ-H2AX foci, we
also observed CTCs with signiﬁcant peripheral γ-H2AX staining
either with or without foci staining. Thus our work suggests that
there may be more than just the presence or absence of γ-H2AX
foci in CTCs and this may have clinical relevance. Also, unless high
magniﬁcation is used, the distinction between peripheral staining,
and nuclear, foci staining, is a challenge.
Several reports exist on the presence of not just speciﬁc“foci”of
staining, but the presence of an “apoptotic ring” which looks very
similar to some of the staining we have seen in the enriched patient
samples (Solier and Pommier, 2009). As the name implies (apop-
totic ring), Solier and Pommier (2009) associate a more diffuse
staining pattern of γ-H2AX in the nucleus to the apoptotic process
and suggest such γ-H2AX staining as another apoptosis marker.
In a separate study, Mukherjee et al. (2006) present evidence
that γ-H2AX is phosphorylated during apoptotic DNA fragmen-
tation and provide images that are similar to ones we present
here.
Finally, it is possible that the peripheral staining is the result of
time/aging of cells that initially had nuclear foci. Most studies of
γ-H2AX staining report a rapid (within hours) appearance of foci
in cancer cell lines in cell culture. Both the lack of knowledge of the
pharmacodynamics in actual patients, the practicality of obtain-
ing blood samples at regular, short intervals, and our knowledge
of the half-life of CTCs in patients blood, precludes our being able
at this point to determine if peripheral staining can be considered
a positive response in the same manner that clear foci are consid-
ered a positive result. For example, the cells that exhibit peripheral
staining in our study could have been circulating in the patient for
several days, or longer, and these same cells initially could have
exhibited focal staining.
Our study underscores the utility and the complexity of investi-
gatingCTCs as predictivemarkers of response to various therapies.
Additional studies are ongoing to evaluate the diverse γ-H2AX
staining patterns we report here which needs to be further cor-
related with patient outcomes. The use of CTCs as a “liquid
biopsy” hold great promise. However, systematic, methodological
studies are needed to evaluate how to develop and test unbiased
multiparameter assays to test markers of interest.
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